user-icon
Position
President
Company
ASCO
Bio
Howard “Skip” Burris III, MD, FACP, FASCO serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology. Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Since joining ASCO in 1991, Dr. Burris has been elected and served as a member of the ASCO Board of Directors (2006-2009) as well as Chair of the Nominating Committee (2012-2013), and he currently serves on the Board of ASCO’s Conquer Cancer Foundation. His committee memberships have included service on Cancer Research, Education, Scientific Program, Research Community Forum, Ethics, Audit, and Sponsorship Committees. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development. Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, began his role as ASCO president-elect in June 2018. An ASCO member for nearly 30 years, Dr. Burris’ service to the Society is extensive. His volunteer roles include member of the ASCO Board of Directors and ASCO’s Conquer Cancer Foundation Board of Directors, chair of the Cancer Research Committee, the Nominating Committee, the Research Community Forum Council, and co-chair of the Ethics Committee. His committee memberships have included the Cancer Education, Scientific Program, Audit, and Sponsorship Committees, among others. Dr. Burris was named a Fellow of ASCO (FASCO) in 2010. Dr. Burris established the first community-based phase I drug development program in Nashville in 1997, which became Sarah Cannon Research Institute. He led the first-in-human studies for many now-approved drugs that have changed the standard of care for several types of cancers. Dr. Burris is president of clinical operations and chief medical officer for Sarah Cannon, the Cancer Institute of HCA Healthcare. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology. Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio.